CCRCC
MCID: CLR030
MIFTS: 54

Clear Cell Renal Cell Carcinoma (CCRCC)

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

MalaCards integrated aliases for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 12 20 58 15
Clear-Cell Metastatic Renal Cell Carcinoma 12 20 71
Clear Cell Carcinoma of Kidney 12 29 6
Conventional Renal Cell Carcinoma 12 71
Renal Clear Cell Carcinoma 12 54
Clear Cell Renal Carcinoma 58 17
Clear Cell Renal Cell Adenocarcinoma 58
Conventional Renal Cell Carcinoma 12
Clear Cell Kidney Carcinoma 12
Cystic-Multilocular Variant 20
Clear Cell Rcc 20
Ccrcc 58

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 44 D002292
NCIt 50 C4033
SNOMED-CT 67 254915003
ICD10 via Orphanet 33 C64
UMLS via Orphanet 72 C0279702
Orphanet 58 ORPHA319276
UMLS 71 C0279702 C2931852

Summaries for Clear Cell Renal Cell Carcinoma

GARD : 20 Clear cell renal cell carcinoma is a cancer of the kidney. The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope. Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass). Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer. Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to renal cell carcinoma, nonpapillary and kidney cancer, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is PBRM1 (Polybromo 1). The drugs Sunitinib and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells.

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 33.2 TUG1 SPRY4-IT1 PVT1 PBRM1 PANDAR OGG1
2 kidney cancer 32.6 PVT1 PBRM1 MEG3 MALAT1
3 chromophobe renal cell carcinoma 31.6 PBRM1 OGG1 HNF1A
4 clear cell papillary renal cell carcinoma 31.3 PBRM1 HNF1A
5 thyroid carcinoma 31.0 PVT1 PANDAR MALAT1
6 intrahepatic cholangiocarcinoma 30.9 TUG1 PBRM1 CCAT2
7 myeloma, multiple 30.8 TUG1 PVT1 MEG3 MALAT1
8 cholangiocarcinoma 30.8 TUG1 SPRY4-IT1 PANDAR OGG1 MALAT1 CCAT2
9 thyroid cancer, nonmedullary, 1 30.8 PVT1 MEG3 MALAT1
10 lung cancer 30.8 TUG1 SPRY4-IT1 PVT1 PANDAR OGG1 MEG3
11 lung squamous cell carcinoma 30.6 TUG1 PVT1 MEG3 CCAT2
12 esophageal cancer 30.6 PVT1 OGG1 MEG3 MALAT1 LUCAT1 CYTOR
13 osteogenic sarcoma 30.6 TUG1 PVT1 PANDAR MEG3 MALAT1 LUCAT1
14 bladder cancer 30.5 TUG1 SPRY4-IT1 PVT1 PCAT29 PANDAR OGG1
15 bladder urothelial carcinoma 30.5 TUG1 PVT1 MEG3 MALAT1
16 oral squamous cell carcinoma 30.5 TUG1 MEG3 MALAT1 CCAT2
17 gallbladder cancer 30.5 TUG1 MEG3 MALAT1 CYTOR
18 pituitary adenoma 30.5 MEG3 MALAT1 CCAT2
19 gastric cancer 30.4 TUG1 SPRY4-IT1 PVT1 PANDAR MEG3 MALAT1
20 lung cancer susceptibility 3 30.3 TUG1 PCAT29 OGG1 MEG3 MALAT1 DRAIC
21 glioblastoma 30.2 TUG1 MEG3 MALAT1 DGCR5 CYTOR
22 multilocular clear cell renal cell carcinoma 11.5
23 hereditary conventional renal cell carcinoma 11.5
24 von hippel-lindau syndrome 11.5
25 multilocular cystic renal neoplasm of low malignant potential 11.4
26 bap1 tumor predisposition syndrome 11.3
27 renal cell carcinoma, xp11-associated 11.2
28 hypoxia 10.8
29 renal cell carcinoma, papillary, 1 10.8
30 chromophil renal cell carcinoma 10.8
31 oncocytoma 10.8
32 angiomyolipoma 10.8
33 hemangioblastoma 10.6
34 renal cell carcinoma 4 10.6
35 severe combined immunodeficiency 10.5
36 body mass index quantitative trait locus 11 10.5
37 body mass index quantitative trait locus 9 10.5
38 body mass index quantitative trait locus 8 10.5
39 body mass index quantitative trait locus 4 10.5
40 body mass index quantitative trait locus 10 10.5
41 body mass index quantitative trait locus 7 10.5
42 body mass index quantitative trait locus 12 10.5
43 body mass index quantitative trait locus 14 10.5
44 body mass index quantitative trait locus 18 10.5
45 body mass index quantitative trait locus 19 10.5
46 renal oncocytoma 10.5
47 exanthem 10.5
48 hypothyroidism 10.5
49 adenocarcinoma 10.5
50 ovarian epithelial cancer 10.5 MEG3 MALAT1 CCAT2

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4 341031-54-7, 557795-19-4 5329102
2 Angiogenesis Inhibitors Phase 4
3 Protein Kinase Inhibitors Phase 4
4
nivolumab Approved Phase 3 946414-94-4
5
Pembrolizumab Approved Phase 3 1374853-91-4
6
Lenvatinib Approved, Investigational Phase 3 417716-92-8
7
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
8
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
9
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
10
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
11 Anti-Infective Agents Phase 3
12 interferons Phase 3
13 Interferon-alpha Phase 3
14 Antiviral Agents Phase 3
15 Interferon alpha-2 Phase 3
16 Pharmaceutical Solutions Phase 3
17 Immunoglobulin G Phase 3
18 Antibodies, Monoclonal Phase 3
19 Immunoglobulins, Intravenous Phase 3
20 Immunosuppressive Agents Phase 3
21 Mitogens Phase 3
22 Endothelial Growth Factors Phase 3
23
Dalteparin Approved Phase 1, Phase 2 9005-49-6
24
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 9812414
25
Tinzaparin Approved Phase 1, Phase 2 9041-08-1, 9005-49-6 25244225
26
Radium Ra 223 dichloride Approved, Investigational Phase 1, Phase 2 444811-40-9
27
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
28
Zoledronic Acid Approved Phase 1, Phase 2 118072-93-8 68740
29
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
30
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
31
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
32
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
33
Busulfan Approved, Investigational Phase 2 55-98-1 2478
34
Acetaminophen Approved Phase 2 103-90-2 1983
35
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
36
Ethanol Approved Phase 2 64-17-5 702
37
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
38
Benzyl alcohol Approved Phase 2 100-51-6 244
39
Promethazine Approved, Investigational Phase 2 60-87-7 4927
40
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
41
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
42
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
43
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
44
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
45
leucovorin Approved Phase 2 58-05-9 6006
46
Selenium Approved, Investigational, Vet_approved Phase 1, Phase 2 7782-49-2
47
Olaparib Approved Phase 2 763113-22-0 23725625
48
Adenosine Approved, Investigational Phase 2 58-61-7 60961
49
Clobetasol Approved, Experimental, Investigational Phase 2 25122-46-7, 25122-41-2 32798 5311051
50
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822

Interventional clinical trials:

(show top 50) (show all 202)
# Name Status NCT ID Phase Drugs
1 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
2 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
3 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
4 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
5 A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) Completed NCT00087022 Phase 3
6 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
7 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
8 Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making. Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
9 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma Completed NCT00326898 Phase 3 Sorafenib Tosylate;Sunitinib Malate
10 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
11 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
12 Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma. Completed NCT00397345 Phase 3
13 A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses Recruiting NCT03849118 Phase 3
14 PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Recruiting NCT03793166 Phase 3 Cabozantinib
15 Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) Recruiting NCT04510597 Phase 3 Active Comparator
16 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Active, not recruiting NCT01120249 Phase 3 everolimus
17 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
18 A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Active, not recruiting NCT01668784 Phase 3 Everolimus
19 An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Not yet recruiting NCT04736706 Phase 3 Belzutifan;Lenvatinib
20 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Terminated NCT02535351 Phase 3 sunitinib or pazopanib
21 Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors Terminated NCT01198158 Phase 3 Everolimus
22 Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC Terminated NCT01599754 Phase 3 Axitinib;Placebo
23 A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
24 An Open Label, Phase IIIB, Single Arm, Multicenter Safety Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma Withdrawn NCT03693573 Phase 3 Atezolizumab;Bevacizumab
25 A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study Unknown status NCT00301990 Phase 2
26 A Phase I/II Trial of Tinzaparin (Innohep), a Low Molecular Weight Heparin (LMWH) for Treatment of Advanced Renal Cell Carcinoma Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
27 Phase I/II Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO®) in Renal Cell Carcinoma Patients With Bone Metastases. Unknown status NCT02880943 Phase 1, Phase 2 XOFIGO
28 A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer Unknown status NCT02960906 Phase 2 Nivolumab;Ipilimumab;Pazopanib;Sunitinib
29 A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy Unknown status NCT01693822 Phase 2 Axitinib
30 Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma Patients: a Prospective Study Unknown status NCT01069770 Phase 2 Sunitinib
31 Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study Unknown status NCT01791387 Phase 2 Dovitinib
32 "PADRES" (Prior Axitinib as a Determinant of Outcome of REnal Surgery) Unknown status NCT03438708 Phase 2 Axitinib Oral Tablet [Inlyta]
33 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Unknown status NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
34 A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma Completed NCT00278174 Phase 2
35 Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma Completed NCT00853021 Phase 2
36 Randomized Phase II Trial Of Sequential ATRA Then IL-2 For Modulation Of Dendritic Cells And Treatment Of Metastatic Renal Cancer Completed NCT00100906 Phase 2 IL-2;ATRA
37 A Phase II Study Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG)In Metastatic Renal Cell Carcinoma Completed NCT00093405 Phase 2 tanespimycin
38 A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer Completed NCT00057889 Phase 2
39 A Phase II, Open-Label, Multicenter Trial of Angiozyme in Subjects With Metastatic Renal Cell Cancer Completed NCT00021021 Phase 2
40 A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors Completed NCT00459979 Phase 2 sunitinib malate
41 Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients With Metastatic Renal Cancer: A Pilot Phase II Study [SuMR] Completed NCT01024205 Phase 2 sunitinib malate
42 A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies Completed NCT02118337 Phase 1, Phase 2
43 Phase I/II Study of Adoptive Immunotherapy Comprising Pyrophosphomonoester Antigen-stimulated T Cells, IL-2, and Nitrogen-containing Bisphosphonates in Patients With Stage IV Renal Cell Carcinoma Completed NCT00588913 Phase 1, Phase 2 zoledronic acid
44 A Dose Escalation Phase II Study of Sunitinib Plus Erlotinib in Advanced Renal Carcinoma Completed NCT00425386 Phase 2 erlotinib hydrochloride;sunitinib malate
45 Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma Completed NCT00401128 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
46 A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma Completed NCT00331409 Phase 2 Everolimus;imatinib mesylate
47 Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A Phase II Study Completed NCT00027573 Phase 2 cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
48 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
49 Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease Completed NCT00523159 Phase 2 Endoxana, IMA901, Leukine;IMA901 and Leukine
50 A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy Completed NCT00866320 Phase 2 sorafenib tosylate

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Genetic tests related to Clear Cell Renal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 29

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

40
Kidney, Endothelial, T Cells, Neutrophil, Prostate, Lymph Node, Pancreas

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 4479)
# Title Authors PMID Year
1
A germline mutation in PBRM1 predisposes to renal cell carcinoma. 6
25911086 2015
2
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. 6
15649945 2005
3
Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway. 6
12574234 2003
4
Bi-allelic inactivation of TCF1 in hepatic adenomas. 6
12355088 2002
5
Hepatocyte nuclear factor 1 alpha (HNF-1 alpha) mutations in maturity-onset diabetes of the young. 6
11058894 2000
6
Alterations of the DNA repair gene OGG1 in human clear cell carcinomas of the kidney. 6
10987279 2000
7
Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. 6
9754819 1998
8
A rapid screening method for hepatocyte nuclear factor 1 alpha frameshift mutations; prevalence in maturity-onset diabetes of the young and late-onset non-insulin dependent diabetes. 6
9439666 1997
9
Identification of mutations in the hepatocyte nuclear factor (HNF)-1 alpha gene in Japanese subjects with IDDM. 6
9313763 1997
10
Mutations in the hepatocyte nuclear factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4. 6
9032114 1997
11
Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3) 6
8945470 1996
12
Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. 6
8866553 1996
13
VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. 61 54
20431476 2010
14
Loss of expression of TIMP3 in clear cell renal cell carcinoma. 61 54
20194016 2010
15
The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. 54 61
19683801 2010
16
Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. 54 61
19963243 2010
17
The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. 61 54
20022054 2010
18
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 61 54
20054297 2010
19
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. 54 61
19695674 2009
20
Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. 54 61
19731255 2009
21
Microarray analysis of microRNA expression in renal clear cell carcinoma. 47
19443172 2009
22
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]. 54 61
20021866 2009
23
Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. 61 54
19219613 2009
24
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. 54 61
19671223 2009
25
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. 54 61
19539328 2009
26
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. 61 54
19402074 2009
27
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. 54 61
19296514 2009
28
[Methylation of promoter region of RASSF1A gene and frequencies of allelic imbalances in chromosome 3 critical regions are correlated with progression of clear cell renal cell carcinoma]. 61 54
19548529 2009
29
Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. 54 61
19302703 2009
30
Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. 54 61
19073886 2009
31
Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. 54 61
19759417 2009
32
Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. 61 54
18660794 2009
33
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. 61 54
18695901 2008
34
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. 54 61
18635227 2008
35
Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. 54 61
18669472 2008
36
Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity. 61 54
18604734 2008
37
Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. 61 54
18538369 2008
38
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. 54 61
18464292 2008
39
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. 54 61
18565906 2008
40
Expression of prostate-specific membrane antigen in renal cortical tumors. 54 61
18344976 2008
41
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. 61 54
18300814 2008
42
Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. 61 54
18076934 2008
43
Expression of claudin-7 in benign kidney and kidney tumors. 61 54
18784823 2008
44
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. 61 54
17997430 2008
45
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. 61 54
18094421 2007
46
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. 54 61
18043042 2007
47
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. 61 54
17947723 2007
48
Characterization of a 3;6 translocation associated with renal cell carcinoma. 61 54
17205537 2007
49
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. 54 61
17382701 2007
50
Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. 61 54
17449941 2007

Variations for Clear Cell Renal Cell Carcinoma

ClinVar genetic disease variations for Clear Cell Renal Cell Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PBRM1 NM_018313.5(PBRM1):c.3923_3930del (p.Asp1308fs) Deletion Pathogenic 218955 rs864321679 3:52597380-52597387 3:52563364-52563371
2 HNF1A NM_000545.6(HNF1A):c.872dup (p.Gly292fs) Duplication Pathogenic 14927 rs587776825 12:121432117-121432118 12:120994314-120994315
3 HNF1A NM_000545.6(HNF1A):c.92G>A (p.Gly31Asp) SNV Pathogenic 14948 rs137853247 12:121416663-121416663 12:120978860-120978860
4 OGG1 NM_002542.5(OGG1):c.137G>A (p.Arg46Gln) SNV Pathogenic 7602 rs104893751 3:9792107-9792107 3:9750423-9750423

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9 (show top 50) (show all 6488)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143616890 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2108A>C p.Q703P 2:184937759-184937759 9
2 COSM88579140 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 9
3 COSM88566796 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 9
4 COSM143612455 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.-135G>C p.? 2:184866378-184866378 9
5 COSM100952565 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 9
6 COSM100946000 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 9
7 COSM85796182 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 9
8 COSM144685741 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 9
9 COSM131496685 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 9
10 COSM94790253 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 9
11 COSM140713700 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2638A>G p.S880G 18:25224620-25224620 9
12 COSM84285389 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 9
13 COSM132161238 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3208G>A p.V1070I 16:49626188-49626188 9
14 COSM136721462 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3379G>A p.V1127I 16:49626188-49626188 9
15 COSM136000826 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3379G>A p.V1127I 16:49626188-49626188 9
16 COSM137730910 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3208G>A p.V1070I 16:49626188-49626188 9
17 COSM137390699 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 9
18 COSM137183617 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3379G>A p.V1127I 16:49626188-49626188 9
19 COSM149268221 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 9
20 COSM102022298 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.4310G>A p.C1437Y 16:72795630-72795630 9
21 COSM102022947 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.-23-8436G>A p.? 16:72959401-72959401 9
22 COSM87274133 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 9
23 COSM87273419 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 9
24 COSM149266502 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 9
25 COSM152022098 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 9
26 COSM89895108 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 9
27 COSM136836927 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1084T>A p.L362I 18:739803-739803 9
28 COSM133267864 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
29 COSM143036610 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
30 COSM145023517 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
31 COSM127993611 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
32 COSM90943050 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
33 COSM126968507 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.-161C>G p.? 11:102114196-102114196 9
34 COSM85232102 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
35 COSM128447153 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
36 COSM94289984 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 9
37 COSM108083403 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 9
38 COSM92180300 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 9
39 COSM108082894 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
40 COSM92179769 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
41 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
42 COSM137057201 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.739G>C p.E247Q 16:69936391-69936391 9
43 COSM96278984 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 16:69936391-69936391 9
44 COSM92965606 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1708G>C p.E570Q 16:69936391-69936391 9
45 COSM149735880 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.536C>A p.P179H 11:32434810-32434810 9
46 COSM91370315 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1432+1G>C p.? 11:32391971-32391971 9
47 COSM113481676 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.536C>A p.P179H 11:32434810-32434810 9
48 COSM111527817 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1372+10G>C p.? 11:32391971-32391971 9
49 COSM130509133 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745+1G>C p.? 11:32391971-32391971 9
50 COSM148578314 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1423+10G>C p.? 11:32391971-32391971 9

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

GO Terms for Clear Cell Renal Cell Carcinoma

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....